Drug Trial Radar · NCT03481634
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Last checked: Nov 20, 2026Latest source record: Jan 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
566
Actual
Start
Jul 23, 2018
Primary completion
Nov 11, 2020
Study completion Oct 18, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
Conditions
- Diabetic Macular Edema
Interventions
BrolucizumabDrug
Intravitreal injection
AfliberceptDrug
Intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52Time frame: Baseline, Week 52
Locations
116 sites in 14 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Beverly Hills, California
Novartis Investigative Site
La Jolla, California
Novartis Investigative Site
Mountain View, California
Novartis Investigative Site
Santa Barbara, California
Novartis Investigative Site
Colorado Springs, Colorado
Novartis Investigative Site
Danbury, Connecticut
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Pensacola, Florida
Novartis Investigative Site
Stuart, Florida
Novartis Investigative Site
‘Aiea, Hawaii
Novartis Investigative Site
Urbana, Illinois
Novartis Investigative Site
Wheaton, Illinois
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
New Albany, Indiana
Novartis Investigative Site
Leawood, Kansas
Novartis Investigative Site
Lenexa, Kansas
Novartis Investigative Site
Paducah, Kentucky
Novartis Investigative Site
Springfield, Massachusetts
Novartis Investigative Site
Stoneham, Massachusetts
Novartis Investigative Site
Reno, Nevada
Novartis Investigative Site
Cincinnati, Ohio
Novartis Investigative Site
Cleveland, Ohio
Novartis Investigative Site
Cleveland, Ohio
Novartis Investigative Site
Kingston, Pennsylvania
Novartis Investigative Site
Philadelphia, Pennsylvania
Novartis Investigative Site
Memphis, Tennessee
Novartis Investigative Site
Nashville, Tennessee
Novartis Investigative Site
Austin, Texas
Novartis Investigative Site
Austin, Texas
Novartis Investigative Site
Austin, Texas
Novartis Investigative Site
Bellaire, Texas
Novartis Investigative Site
Harlingen, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
San Antonio, Texas
Novartis Investigative Site
Tyler, Texas
Novartis Investigative Site
Silverdale, Washington
Novartis Investigative Site
Spokane, Washington
Novartis Investigative Site
Madison, Wisconsin
Novartis Investigative Site
CABA, Argentina
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.